GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Median PS Value

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Median PS Value : $0.00 (As of May. 06, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Advanced Proteome Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2023 was $0. Advanced Proteome Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-06), Advanced Proteome Therapeutics's share price is $0.0002. Advanced Proteome Therapeutics's Median PS Value is $0.00. Therefore, Advanced Proteome Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Advanced Proteome Therapeutics's Median PS Value or its related term are showing as below:

APTCF's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Advanced Proteome Therapeutics Median PS Value Historical Data

The historical data trend for Advanced Proteome Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Median PS Value Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advanced Proteome Therapeutics's Median PS Value

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Price-to-Median-PS-Value falls into.



Advanced Proteome Therapeutics Median PS Value Calculation

Advanced Proteome Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Advanced Proteome Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Proteome Therapeutics  (OTCPK:APTCF) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Advanced Proteome Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0002/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Proteome Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines